BRIXADI

NDC 58284-264 · Braeburn Inc.

Generic nameBUPRENORPHINE

Dosage formINJECTION

RouteSUBCUTANEOUS

Active ingredient(s)BUPRENORPHINE

Strength64 mg/.18mL

Pharmacologic classPartial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]

DEA scheduleCIII

Marketing categoryNDA

Packages

58284-264-01 — 1 SYRINGE, GLASS in 1 CARTON (58284-264-01) / .18 mL in 1 SYRINGE, GLASS

Billed under HCPCS

J0578 — Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy Medicare Part B payment limit (ASP + 6%): $1722.31

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

50742-373 — Buprenorphine, 50742-374 — Buprenorphine, 50742-375 — Buprenorphine, 50742-376 — Buprenorphine, 58064-408 — buprenorphine, 58284-208 — BUPRENORPHINE, 58284-216 — BUPRENORPHINE, 58284-224 — BUPRENORPHINE, 58284-228 — BUPRENORPHINE, 58284-232 — BUPRENORPHINE, 58284-296 — BUPRENORPHINE, 59011-750 — buprenorphine, 59011-751 — buprenorphine, 59011-752 — buprenorphine, 59011-757 — buprenorphine, 59011-758 — buprenorphine, 62175-452 — Buprenorphine and Naloxone, 62175-458 — Buprenorphine and Naloxone, 69238-1202 — Buprenorphine, 69238-1203 — Buprenorphine, +27 more

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.